The independent source for health policy research, polling, and news.
441-460 of 707 results
Utah's Orrin Hatch is leaving the Senate, after 42 years. The Republican led bipartisan efforts to provide health care to more kids and AIDS patients. He also thrived on donations from the drug industry.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
The fallout continues from that Texas court decision that ruled Congress鈥 2017 elimination of the tax penalty for failing to have insurance rendered the entire Affordable Care Act unconstitutional. Meanwhile, enrollment for 2019 at healthcare.gov was down, but far less than many predicted. KHN鈥檚 Julie Rovner, along with panelists Joanne Kenen of Politico, Anna Edney of Bloomberg News and Kimberly Leonard of the Washington Examiner, discuss this, plus the best, most overhyped and nerdiest stories of 2018. Also, Rovner interviews GOP strategist and pollster Frank Luntz.
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from 鈥渂iosimilars.鈥 It鈥檚 a very different story in Europe.
The leaders of California鈥檚 legislative health committees who wield power over state health policy have been showered with money from the health care sector, with drug companies, health plans, hospitals and doctors providing nearly 40 percent of their 2017-18 campaign funds.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
It鈥檚 a little-known secret that patients can get thousands of dollars directly from a drugmaker.
The case of a Michigan woman told to fundraise $10,000 for a heart transplant sparked viral outrage, but experts say 鈥渨allet biopsies鈥 are common.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN鈥檚 Jay Hancock about the latest 鈥淏ill of the Month.鈥
Top House Republican also received more than $1 million from drugmakers since 2007.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn鈥檛 find the same promise for over-the-counter fish oil supplements when tested in healthy people.
KHN鈥檚 Sarah Jane Tribble discusses the twists and turns with CBS News.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats鈥 takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.
Democrats, who have a history of championing the Affordable Care Act and railing about drug prices, will now chair several house committees.
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Joanne Kenen of Politico discuss the start of open enrollment for individual health insurance plans for 2019 and preview what next week鈥檚 midterm elections might mean for health policy. Plus, Barbara Feder Ostrov of KHN and California Healthline talks to Julie about the latest NPR-KHN 鈥淏ill of the Month鈥 feature.
Medical treatments targeting the DNA in tumor cells are celebrated, but insurers often won鈥檛 cover the skyrocketing cost.
漏 2026 KFF